Ovarian Cancer’s Hidden Threat? It’s in the Fluid, Not the TumorResearch reveals how ascites in ovarian cancer disrupts immunity, hindering tumor defense but offers potential treatment solutions.
Corcept’s New Cancer Pill Boosts Survival for Drug-Resistant PatientsCorcept's Relacorilant shows promise in treating platinum-resistant ovarian cancer, extending survival by 4.5 months in trials.
Ovarian Cancer: Early Detection and Prevention StrategiesOvarian cancer, the deadliest gynecological cancer, is often diagnosed late; early detection can significantly improve survival rates.
Must-Reads
1
Shaw Prize winner Baumeister on breakthroughs that changed cell imaging
LATEST
2
Coach-athlete interaction at marathon finish sparks online debate
LATEST
3
Seoul shares snap 2-day drop on hopes for rate cut, eased AI fear; won rebounds
LATEST
4
Hanwha revamps US investment arm for defense push
LATEST
5
S. Korea asks Lone Star to reimburse legal costs after winning annulment in investor dispute
Ovarian Cancer’s Hidden Threat? It’s in the Fluid, Not the Tumor Research reveals how ascites in ovarian cancer disrupts immunity, hindering tumor defense but offers potential treatment solutions.
Corcept’s New Cancer Pill Boosts Survival for Drug-Resistant Patients Corcept's Relacorilant shows promise in treating platinum-resistant ovarian cancer, extending survival by 4.5 months in trials.
Ovarian Cancer: Early Detection and Prevention Strategies Ovarian cancer, the deadliest gynecological cancer, is often diagnosed late; early detection can significantly improve survival rates.
Hot Topics